StemCyte International, Ltd. (TPE:4178)
Taiwan · Delayed Price · Currency is TWD 19.60
+1.55 (8.59%)
At close: Oct 8, 2026
StemCyte International Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2013 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '13 Dec 31, 2013 |
| 362.99 | 368.91 | 382.69 | 362.78 | 347.69 | 857.07 | |
Revenue Growth | -7.32% | -3.60% | 5.49% | 4.34% | -59.43% | 16.97% |
Cost of Revenue | 248.7 | 242.09 | 264.71 | 257.09 | 225.35 | 406.64 |
Gross Profit | 114.29 | 126.82 | 117.98 | 105.69 | 122.33 | 450.43 |
Selling, General & Admin | 247.43 | 247.98 | 241.61 | 216.51 | 187.29 | 498.3 |
Research & Development | 98.62 | 101.81 | 128.5 | 127.36 | 83.72 | 33.27 |
Operating Expenses | 350.18 | 351.99 | 376.33 | 351.11 | 281.87 | 531.57 |
Operating Income | -235.89 | -225.17 | -258.35 | -245.42 | -159.54 | -81.14 |
Interest Expense | -12.48 | -13.14 | -10.82 | -1.92 | -2.76 | -1.52 |
Interest & Investment Income | 79.81 | 81.37 | 62.7 | 21.58 | 2.38 | 19.94 |
Earnings From Equity Investments | - | - | - | - | -0.67 | - |
Currency Exchange Gain (Loss) | 16.9 | -10.47 | -2.05 | -0.64 | 0.99 | - |
Other Non Operating Income (Expenses) | -1.52 | -0.03 | 5.05 | -9.97 | 31.3 | -2.14 |
EBT Excluding Unusual Items | -153.18 | -167.43 | -203.46 | -236.36 | -128.3 | -64.86 |
Impairment of Goodwill | - | - | - | -32.04 | - | - |
Gain (Loss) on Sale of Assets | -0 | -0.48 | - | - | -0.03 | - |
Asset Writedown | -18 | -5.23 | -1.45 | -63.2 | - | - |
Pretax Income | -168.67 | -173.14 | -204.92 | -331.59 | -128.33 | -64.86 |
Income Tax Expense | 3.63 | 3.67 | 0.74 | -11.83 | -5.98 | - |
Earnings From Continuing Operations | -172.31 | -176.81 | -205.66 | -319.76 | -122.35 | -64.86 |
Earnings From Discontinued Operations | - | - | - | - | 60.94 | - |
Net Income to Company | -172.31 | -176.81 | -205.66 | -319.76 | -61.41 | -64.86 |
Minority Interest in Earnings | - | - | - | - | 6.91 | 4.69 |
Net Income | -172.31 | -176.81 | -205.66 | -319.76 | -54.5 | -60.17 |
Net Income to Common | -172.31 | -176.81 | -205.66 | -319.76 | -54.5 | -60.17 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 197 | 192 | 180 | 144 | 139 | 78 |
Shares Outstanding (Diluted) | 197 | 192 | 180 | 144 | 139 | 78 |
Shares Change | 0.75% | 6.37% | 24.91% | 3.60% | 79.13% | -2.42% |
EPS (Basic) | -0.88 | -0.92 | -1.14 | -2.21 | -0.39 | -0.77 |
EPS (Diluted) | -0.88 | -0.92 | -1.14 | -2.21 | -0.39 | -0.77 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2013 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '13 Dec 31, 2013 |
Free Cash Flow | -54.89 | -54.9 | -171.89 | -98.08 | -40.85 | -316.01 |
Free Cash Flow Per Share | -0.28 | -0.29 | -0.95 | -0.68 | -0.29 | -4.06 |
Gross Margin | 31.49% | 34.38% | 30.83% | 29.13% | 35.19% | 52.55% |
Operating Margin | -64.99% | -61.04% | -67.51% | -67.65% | -45.88% | -9.47% |
Profit Margin | -47.47% | -47.93% | -53.74% | -88.14% | -15.68% | -7.02% |
Free Cash Flow Margin | -15.12% | -14.88% | -44.92% | -27.04% | -11.75% | -36.87% |
EBITDA | -209 | -196.93 | -229.06 | -209.89 | -122.67 | -54.68 |
EBITDA Margin | -57.58% | -53.38% | -59.86% | -57.86% | -35.28% | -6.38% |
D&A For EBITDA | 26.9 | 28.25 | 29.29 | 35.53 | 36.87 | 26.46 |
EBIT | -235.89 | -225.17 | -258.35 | -245.42 | -159.54 | -81.14 |
EBIT Margin | -64.99% | -61.04% | -67.51% | -67.65% | -45.88% | -9.47% |